Literature DB >> 8080986

Retroviral vector design for long-term expression in murine hematopoietic cells in vivo.

P H Correll1, S Colilla, S Karlsson.   

Abstract

A series of retroviral vectors containing the human glucocerebrosidase (GC) cDNA driven by various promoters have been constructed in an attempt to discover which vector design can most efficiently transduce murine hematopoietic stem cells (HSCs) and drive expression of the transferred gene in hematopoietic cells of mice reconstituted with the transduced stem cells. The simplest vector, LG, in which the GC gene is driven by the viral LTR, was the most efficient vector at infecting HSCs, with an average viral copy number in hematopoietic tissues of 3 copies/cell in recipient mice. In general, the viral vectors that contained any additional promoters or enhancers to drive expression of either the GC gene or a selectable marker gene (Neo) had lower titers and/or transduced HSCs at a lower efficiency. This was seen most markedly when the human phosphoglycerate (PGK) promoter was used to drive the human GC cDNA. Despite repeated attempts to obtain a high titer producer clone, this virus consistently produced low titers and subsequently resulted in the lowest proviral copy numbers in long-term reconstituted mice. Only the viral LTR and PGK promoter were capable of driving significant levels of human GC RNA in hematopoietic cells of long-term reconstituted mice, with a much lower level of RNA generated by an internal herpes TK or SV40 immediate early promoter. Insertion of the internal transcription unit in the opposite orientation relative to the viral LTRs had a detrimental effect on gene expression. The levels of RNA generated by a hybrid LTR containing the myeloproliferative sarcoma virus enhancer were higher in bone marrow-derived macrophages than in nonadherent cells of the bone marrow when compared with the LG vector. The presence of an internal promoter to drive expression of the human GC cDNA did not seem to have a detrimental effect on expression levels from the viral LTR. In fact, in the presence of an internal TK or PGK promoter expression from the LTR was increased despite the presence of lower proviral copy numbers. Insertion of a second gene (Neo) into the vector had a negative impact on long-term expression in hematopoietic cells in vivo; however, this seems to be due solely to the lower transduction efficiency of this vector. Overall, the highest levels of GC activity in macrophages of long-term reconstituted mice were generated by the LG vector; however, these levels were variable.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080986

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Gene transfer approaches to the lysosomal storage disorders.

Authors:  J A Barranger; E O Rice; W P Swaney
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

2.  Lentivirus gene transfer in murine hematopoietic progenitor cells is compromised by a delay in proviral integration and results in transduction mosaicism and heterogeneous gene expression in progeny cells.

Authors:  H Mikkola; N B Woods; M Sjögren; H Helgadottir; I Hamaguchi; S E Jacobsen; D Trono; S Karlsson
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Long-term in vivo expression of the human glucocerebrosidase gene in nonhuman primates after CD34+ hematopoietic cell transduction with cell-free retroviral vector preparations.

Authors:  L C Xu; S Karlsson; E R Byrne; S Kluepfel-Stahl; S W Kessler; B A Agricola; S Sellers; M Kirby; C E Dunbar; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

4.  Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy.

Authors:  P M Cannon; N Kim; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Development of a self-inactivating lentivirus vector.

Authors:  H Miyoshi; U Blömer; M Takahashi; F H Gage; I M Verma
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector.

Authors:  J A Medin; M Tudor; R Simovitch; J M Quirk; S Jacobson; G J Murray; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

7.  Ectopic TAL-1/SCL expression in phenotypically normal or leukemic myeloid precursors: proliferative and antiapoptotic effects coupled with a differentiation blockade.

Authors:  G L Condorelli; A Tocci; R Botta; F Facchiano; U Testa; L Vitelli; M Valtieri; C M Croce; C Peschle
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

8.  Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11.

Authors:  R G Hawley; T S Hawley; A Z Fong; C Quinto; M Collins; J P Leonard; S J Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

9.  Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors.

Authors:  M Migita; J A Medin; R Pawliuk; S Jacobson; J W Nagle; S Anderson; M Amiri; R K Humphries; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

10.  Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy.

Authors:  M Miyauchi; H Shimada; K Kadomatsu; T Muramatsu; S Matsubara; S Ikematsu; K Takenaga; T Asano; T Ochiai; S Sakiyama; M Tagawa
Journal:  Jpn J Cancer Res       Date:  1999-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.